Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer1,2. In patients with myelodysplastic syndromes (MDS), TP53 mutations are associated with high-risk disease3,4, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies6,7,8 and dismal outcomes9....

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Bernard, E, Nannya, Y, Hasserjian, RP, Boultwood, J, Pellagatti, A
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	Springer Nature 2020

Παρόμοια τεκμήρια

NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
ανά: Fidler, C, κ.ά.
Έκδοση: (2004)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
ανά: Ramy Rahmé, κ.ά.
Έκδοση: (2023-04-01)

Rare case of myelodysplastic syndrome with near-tetraploidy and TP53 mutation
ανά: Čolović Nataša, κ.ά.
Έκδοση: (2023-01-01)

Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes
ανά: Lijuan Zhang, κ.ά.
Έκδοση: (2023-12-01)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
ανά: Haase, D, κ.ά.
Έκδοση: (2019)

SF3B1 mutant myelodysplastic syndrome: Recent advances
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2020)

TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome
ανά: Pimjai Niparuck, κ.ά.
Έκδοση: (2021-10-01)

Gene expression profiling in the myelodysplastic syndromes.
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2005)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2016)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
ανά: Davidson Zhao, κ.ά.
Έκδοση: (2023-03-01)

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.
ανά: Boultwood, J, κ.ά.
Έκδοση: (2014)

TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions
ανά: Daver, NG, κ.ά.
Έκδοση: (2022)

Single-molecule DNA sequencing of acute myeloid leukemia and myelodysplastic syndromes with multiple TP53 alterations
ανά: Laurence Lodé, κ.ά.
Έκδοση: (2018-01-01)

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
ανά: Rashmi Kanagal-Shamanna, κ.ά.
Έκδοση: (2021-03-01)

A tale of two alleles: TP53 and transformation in MPNs
ανά: Brierley, C, κ.ά.
Έκδοση: (2022)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation
ανά: Liberante, F, κ.ά.
Έκδοση: (2013)

High and low, but not intermediate, PRAME expression levels are poor prognostic markers in myelodysplastic syndrome at disease presentation.
ανά: Liberante, F, κ.ά.
Έκδοση: (2013)

Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should
ανά: Corey Cutler
Έκδοση: (2017-12-01)

Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports
ανά: Fernando Barroso Duarte, κ.ά.
Έκδοση: (2017-05-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
ανά: Armstrong, R, κ.ά.
Έκδοση: (2017)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
ανά: Nikeeta Mandhan, κ.ά.
Έκδοση: (2022-01-01)

Clonality in the myelodysplastic syndromes.
ανά: Boultwood, J, κ.ά.
Έκδοση: (2001)

To target the untargetable: elucidation of synergy of APR-246 and azacitidine in TP53 mutant myelodysplastic syndromes and acute myeloid leukemia
ανά: David A. Sallman
Έκδοση: (2020-06-01)

PB1913: SYNERGISTIC EFFECTS OF DECITABINE AND APR-246 IN TP53 P.248Q-MUTATED MYELODYSPLASTIC SYNDROME
ανά: Y. Fang, κ.ά.
Έκδοση: (2022-06-01)

Prognostic heterogeneity and clonal dynamics within distinct subgroups of myelodysplastic syndrome and acute myeloid leukemia with TP53 disruptions
ανά: Shyam A. Patel, κ.ά.
Έκδοση: (2023-11-01)

Pulmonary infection associated with immune dysfunction is associated with poor prognosis in patients with myelodysplastic syndrome accompanied by TP53 abnormalities
ανά: Yi Chen, κ.ά.
Έκδοση: (2023-11-01)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia
ανά: Kathy L. McGraw, κ.ά.
Έκδοση: (2016-08-01)

Molecular pathogenesis of the myelodysplastic syndromes
ανά: Boultwood, J, κ.ά.
Έκδοση: (1999)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
ανά: Boultwood, J, κ.ά.
Έκδοση: (2012)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
ανά: Melania Tesio
Έκδοση: (2023-02-01)

Telomere length in myelodysplastic syndromes.
ανά: Boultwood, J, κ.ά.
Έκδοση: (1995)

Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
ανά: Nabih Maslah, κ.ά.
Έκδοση: (2020-06-01)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
ανά: Yuxin Wang, κ.ά.
Έκδοση: (2022-07-01)

Gene expression profiling in 5q-syndrome and myelodysplastic syndromes.
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2003)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
ανά: Haiwei Wang, κ.ά.
Έκδοση: (2022-06-01)

The role and impact of Del(5q) and TP53 mutations on haematopoietic stem and progenitor cells during the progression of Myelodysplastic Syndrome to Acute Myeloid Leukaemia
ανά: Doolittle, H
Έκδοση: (2017)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma
ανά: Alexander Quaas, κ.ά.
Έκδοση: (2019-01-01)

Gene Expression Profiling of CD34(+) Cells in Patients with Myelodysplastic Syndromes
ανά: Pellagatti, A, κ.ά.
Έκδοση: (2008)

P066: Variant overlooked: A partial deficiency TP53 allele that skirts interpretation criteria
ανά: Lisa Lansdon, κ.ά.
Έκδοση: (2023-01-01)

Clinical and biological implications of driver mutations in myelodysplastic syndromes.
ανά: Papaemmanuil, E, κ.ά.
Έκδοση: (2013)